Oncoinvent Outlines Phase III Clinical Trial Scope and Extends Cash Runway to 2027
Oncoinvent ASA (BRRGF) has provided updates regarding its clinical development strategy, specifically outlining a Phase III trial expected to involve approximately 500 to 600 patients. As of the end of Q3, the company has successfully recruited 71 patients and expanded its operations to include 11 clinical sites, including the Hospital of Saint-Luc in Brussels. Financially, the company reported an extended cash runway reaching into the second half of 2027. This extension provides a significant buffer for ongoing clinical activities and operational requirements as the firm progresses through its current development milestones.